Abstract
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID‐19) and is important for oncology patients. mRNA‐based COVID‐19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG‐ASNase) and those with PEG‐ASNase‐associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID‐19 vaccines. We, therefore, surveyed oncologists on COVID‐19 vaccine counseling practice and vaccination outcomes in COVID‐19 vaccination‐eligible patients and show safe receipt of mRNA vaccines despite PEG‐ASNase hypersensitivity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
